Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-Ku, Kawasaki, Kanagawa, 216-8511, Japan.
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
CEN Case Rep. 2023 May;12(2):215-220. doi: 10.1007/s13730-022-00756-5. Epub 2022 Nov 18.
Excessive immunosuppression after kidney transplantation (KT) is often encountered in patients undergoing therapy for anti-rejection or autoimmune disease that requires further treatment using immunosuppressive medications (IMs), including biologic agents. We report a novel case wherein a kidney transplant recipient developed severe acute allograft injury and hemorrhagic cystitis at 4.5 years after KT due to adenovirus nephritis after treatment with infliximab for Crohn's disease. The diagnosis was made based on adenovirus immunohistochemistry staining and urine polymerase chain reaction tests. The patient was successfully treated by reducing IMs and administration of immunoglobulin even though allograft function was eventually partially recovered. When new immunosuppressive agents, particularly biologic agents, are initiated for other diseases in addition to maintenance IMs, the following points need to be regarded: (1) pay attention to opportunistic infections even in the late phase of KT, and (2) maintain communication with other specialists who prescribe biologics to ensure appropriate administration of IMs.
肾移植(KT)后过度免疫抑制在接受抗排斥或自身免疫性疾病治疗的患者中经常遇到,需要进一步使用免疫抑制药物(IMs)治疗,包括生物制剂。我们报告了一例新的病例,一名 KT 后 4.5 年的肾移植受者在接受英夫利昔单抗治疗克罗恩病后因腺病毒肾炎而发生严重急性移植物损伤和出血性膀胱炎。根据腺病毒免疫组织化学染色和尿聚合酶链反应试验做出诊断。尽管移植物功能最终部分恢复,但通过减少 IMs 和免疫球蛋白的给予,患者成功得到治疗。当除维持 IMs 外还开始使用新的免疫抑制剂,特别是生物制剂治疗其他疾病时,需要注意以下几点:(1)即使在 KT 的晚期也要注意机会性感染,(2)与开生物制剂的其他专科医生保持沟通,以确保 IMs 的合理使用。